Administrative Core

管理核心 IPCAVD行政核心将负责协调公爵的所有科学和行政活动 IPCAVD，确保项目和核心一起很好地运作。核心的主要活动将是 监测IPCAVD相对于里程碑的进展，并对照可用资金衡量这一进展，以 确保资源得到有效利用。核心将协调外部咨询委员会的工作 (EAC)，将审查项目和核心的进展情况，并为计划的 方向。核心员工是经验丰富的综合管理团队的一部分，这将使 开工快、进度快。这种团队合作将加速该计划的进展 目标，从而最大限度地增加对人类艾滋病毒-1疫苗研究产生积极影响的机会。具体的 行政核心的目标如下。 目标1.全面管理、协调和监督IPCAVD计划。 目标2.确保及时进行财务会计和报告。 目标3.确保遵守所有机构、州和联邦研究以及CGMP指南。 目标4.制定和实施IPCAVD通信、出版和数据共享计划。 目标5.为所有数据分析提供统计支持。 IPCAVD管理核心将促进项目1、项目2和动物项目的成功整合 Models Core支持开发两种用于临床试验的信使核糖核酸临床试验材料的总体计划目标 第五年的第一阶段临床试验。作为一个功能最佳的核心，它将支持核苷的开发- 修饰的mRNAs是一种重要的新的HIV-1疫苗平台，可能会改变HIV-1疫苗 通过提供免疫原来启动bNab谱系并诱导持久的免疫反应。

Administrative Core The IPCAVD Administrative Core will serve to coordinate all scientific and administrative activities of the Duke IPCAVD, ensuring that the Projects and Cores function well together. A primary activity of the Core will be monitoring IPCAVD progress relative to milestones and measuring this progress against available funding to ensure resources are used efficiently. The Core will coordinate the effort of an External Advisory Committee (EAC) that will review the progress of the Projects and Cores and provide critical guidance for the Program's direction. Core staff are part of a highly experienced and integrated management team, which will enable immediate start-up and rapid progress. This teamwork will accelerate advancement toward the Program's goals, thus maximizing the opportunities to positively impact HIV-1 vaccine research in humans. The Specific Aims of the Administrative Core are as follows. Aim 1. Provide overall IPCAVD management, coordination and supervision of the Program. Aim 2. Ensure timely financial accounting and reporting. Aim 3. Ensure compliance with all institutional, state, and federal research and CGMP guidelines. Aim 4. Develop and implement an IPCAVD communication, publication, and data sharing plan. Aim 5. Provide statistical support for all data analyses. The IPCAVD Administrative Core will facilitate the successful integration of Project 1, Project 2, and the Animal Models Core to support the overall Program goal to develop two mRNA clinical trials materials for testing in a Phase 1 clinical trial in year 5. As an optimally functioning Core, it will support development of nucleoside- modified mRNAs an important new HIV-1 vaccine platform that potentially can transform the HIV-1 vaccine field by providing immunogens to initiate bnAb lineages and induce durable immune responses.